Search Results - Atef Halabi

  • Showing 1 - 4 results of 4
Refine Results
  1. 1

    Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment by Magda S. C. Fontes, Jasper Dingemanse, Atef Halabi, Monika Tomaszewska-Kiecana, Patricia N. Sidharta

    Published in Scientific Reports (2022-11-01)
    Get full text
    Article


  2. 2

    Pharmacokinetic evaluation of single-dose migalastat in non-Fabry disease subjects with ESRD receiving dialysis treatment, and use of modeling to select dose regimens in Fabry dise... by Franklin K Johnson, Shirley Wu, Ginny Schmith, Hadis Williams, Jasmine Rutecki, Atef Halabi, Thorsten Feldkamp, Anthony Sileno

    Published in PLoS ONE (2024-01-01)
    Get full text
    Article


  3. 3

    The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design St... by HeeJae Choi, Shilpa Madari, Elmar Daalman, Brett A. English, Atef Halabi, Kathrin Hohl, Yury Shatillo, Nathalie Weidinger, Michael Desch

    Published in Drugs in R&D (2026-03-01)
    Get full text
    Article


  4. 4

    New strategies to improve clinical outcomes for diabetic kidney disease by Thomas Forst, Chantal Mathieu, Francesco Giorgino, David C. Wheeler, Nikolaos Papanas, Roland E. Schmieder, Atef Halabi, Oliver Schnell, Marina Streckbein, Katherine R. Tuttle

    Published in BMC Medicine (2022-10-01)
    Get full text
    Article


Search Tools: